Psychosocial Outcomes in Adult Survivors of Retinoblastoma [Palliative and Supportive Care]
Purpose Survival rates for individuals diagnosed with retinoblastoma (RB) exceed 95% in the United States; however, little is known about the long-term psychosocial outcomes of these survivors. Patients and Methods Adult RB survivors, diagnosed from 1932 to 1994 and treated in New York, completed a comprehensive questionnaire adapted from the Childhood Cancer Survivor Study (CCSS), by mail or telephone. Psychosocial outcomes included psychological distress, anxiety, depression, somatization, fear of cancer recurrence, satisfaction with facial appearance, post-traumatic growth, and post-traumatic stress symptoms; noncancer...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Ford, Chou, Sklar, Oeffinger, Novetsky Friedman, McCabe, Robison, Kleinerman, Li, Marr, Abramson, Dunkel Tags: Retinoblastoma, Quality of Life, Supportive Care Palliative and Supportive Care Source Type: research

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) [Gastrointestinal Cancer]
Conclusion Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Guercio, Sato, Niedzwiecki, Ye, Saltz, Mayer, Mowat, Whittom, Hantel, Benson, Atienza, Messino, Kindler, Venook, Hu, Ogino, Wu, Willett, Giovannucci, Meyerhardt, Fuchs Tags: Epidemiology, Diagnosis & Staging, Gastrointestinal Gastrointestinal Cancer Source Type: research

Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study [Gastrointestinal Cancer]
Conclusion Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin. Such patients are likely to benefit from obesity prevention and/or regular aspirin. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Movahedi, Bishop, Macrae, Mecklin, Moeslein, Olschwang, Eccles, Evans, Maher, Bertario, Bisgaard, Dunlop, Ho, Hodgson, Lindblom, Lubinski, Morrison, Murday, Ramesar, Side, Scott, Thomas, Vasen, Burn, Mathers Tags: Epidemiology Gastrointestinal Cancer Source Type: research

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology [Clinical Trials]
Purpose The decision by journals to append protocols to published reports of randomized trials was a landmark event in clinical trial reporting. However, limited information is available on how this initiative effected transparency and selective reporting of clinical trial data. Methods We analyzed 74 oncology-based randomized trials published in Journal of Clinical Oncology, the New England Journal of Medicine, and The Lancet in 2012. To ascertain integrity of reporting, we compared published reports with their respective appended protocols with regard to primary end points, nonprimary end points, unplanned end points, a...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Raghav, Mahajan, Yao, Hobbs, Berry, Pentz, Tam, Hong, Ellis, Abbruzzese, Overman Tags: Clinical Trials Source Type: research

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma [Gynecologic Cancer]
Conclusion Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Oza, Pignata, Poveda, McCormack, Clamp, Schwartz, Cheng, Li, Campbell, Dodion, Haluska Tags: Chemotherapy, Combined Modality, Translational Oncology Gynecologic Cancer Source Type: research

Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort [Pediatric Oncology]
Purpose Survivors of childhood cancer have an increased risk for subsequent neoplasms (SNs), but the incidence beyond the age of 40 years and associations with therapeutic exposures have not been well described. Patients and Methods Among 14,364 survivors of childhood cancer diagnosed between 1970 and 1986, 3,171 had an attained age of 40 years or older at the time of last contact. Cumulative incidence of SNs, standardized incidence ratios (SIRs), excess absolute risk of subsequent malignant neoplasms (SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated. Results In total, 679 SNs were di...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Turcotte, Whitton, Friedman, Hammond, Armstrong, Leisenring, Robison, Neglia Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial [Health Services and Outcomes]
Purpose We tested whether prospective use of electronic health record-based trigger algorithms to identify patients at risk of diagnostic delays could prevent delays in diagnostic evaluation for cancer. Methods We performed a cluster randomized controlled trial of primary care providers (PCPs) at two sites to test whether triggers that prospectively identify patients with potential delays in diagnostic evaluation for lung, colorectal, or prostate cancer can reduce time to follow-up diagnostic evaluation. Intervention steps included queries of the electronic health record repository for patients with abnormal findings and ...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Murphy, Wu, Thomas, Forjuoh, Meyer, Singh Tags: Quality of Care, Policy Analysis Health Services and Outcomes Source Type: research

Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial [Health Services and Outcomes]
Conclusion The present trial showed no evidence of a benefit of SCPs on satisfaction with information and care. Furthermore, SCPs increased patients' concerns, emotional impact, experienced symptoms, and the amount of cancer-related contact with the primary care physician. Whether this may ultimately lead to more empowered patients should be investigated further. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Nicolaije, Ezendam, Vos, Pijnenborg, Boll, Boss, Hermans, Engelhart, Haartsen, Pijlman, van Loon-Baelemans, Mertens, Nolting, van Beek, Roukema, Zijlstra, Kruitwagen, van de Poll-Franse Tags: Quality of Care Health Services and Outcomes Source Type: research

High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer [Genetic Testing for Cancer]
Conclusion We conclude that patients diagnosed with CRC at age 35 years or younger should receive genetic counseling regardless of their family history and phenotype. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Mork, You, Ying, Bannon, Lynch, Rodriguez-Bigas, Vilar Tags: Epidemiology Genetic Testing for Cancer Source Type: research

Pseudoprogression and Immune-Related Response in Solid Tumors [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Chiou, Burotto Tags: Clinical Trials, Immunology/Immunobiology COMMENTS AND CONTROVERSIES Source Type: research

Second-Line Therapy for Endometrial Cancer: The Need for Better Options [ONCOLOGY GRAND ROUNDS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Fleming Tags: Oncology Grand Rounds Source Type: research

Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Yu, Vose, Hayes Tags: ASCO Guidelines EDITORIALS Source Type: research

Surveillance of Childhood Cancer Survivors: A Lifelong Affair [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Applebaum, Cohn Tags: Long Term Survival & Late Effects EDITORIALS Source Type: research

Avoiding Implementation Errors in Cancer Survivorship Care Plan Effectiveness Studies [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Mayer, Birken, Chen Tags: Outcomes Research, Quality of Care EDITORIALS Source Type: research

Colorectal Cancer in Young Individuals: Opportunities for Prevention [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Stoffel Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Graziano, de Marinis, Gori, Gasbarra, Migliorino, De Santis, Pelosi, Leone Tags: Translational Oncology, Diagnosis & Staging, Pathology, CT, Lung, Thoracic DIAGNOSIS IN ONCOLOGY Source Type: research

ERRATA [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Tags: Errata Source Type: research

Reply to G.D. Aletti et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Horowitz, Miller, Rungruang, Richard, Rodriguez, Bookman, Hamilton, Krivak, Maxwell Tags: CORRESPONDENCE Source Type: research

There Is Nothing New Under the Sun [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Aletti, Bristow, Chi, Cliby Tags: CORRESPONDENCE Source Type: research

Reply to M.H. Kanter et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Rhoads, Patel, Ma, Schmidt Tags: CORRESPONDENCE Source Type: research

Integration Alone Does Not Reduce Health Care Disparities [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Kanter, Schottinger, Copeland Tags: CORRESPONDENCE Source Type: research

Reply to S. Debska-Szmich et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Van Cutsem, Beier, Ciardiello Tags: CORRESPONDENCE Source Type: research

Selection of Patients for Anti-Epidermal Growth Factor Receptor Treatment in Colorectal Cancer: The Potential Pitfalls of Retrospective Analyses of RAS Mutations [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Debska-Szmich, Krakowska, Potemski Tags: CORRESPONDENCE Source Type: research

Reply to G. Bogani et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Slomovitz, Coleman Tags: CORRESPONDENCE Source Type: research

Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Bogani, Chiappa, Lorusso, Raspagliesi Tags: CORRESPONDENCE Source Type: research

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [ASCO SPECIAL ARTICLES]
Purpose To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer (NSCLC). Methods An Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendations on a systematic review of randomized controlled trials from January 2007 to February 2014. Results This guideline update reflects changes in evidence since the previous guideline. Recommendations There is no cure for patients with stage IV NSCLC. For patients with performance status (PS) 0 to 1 (and appropriate patient cases...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Masters, Temin, Azzoli, Giaccone, Baker, Brahmer, Ellis, Gajra, Rackear, Schiller, Smith, Strawn, Trent, Johnson Tags: ASCO Guidelines, Chemotherapy, Combined Modality ASCO SPECIAL ARTICLES Source Type: research

WEE1 Kinase As a Target for Cancer Therapy [UNDERSTANDING THE PATHWAY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Mueller, Haas-Kogan Tags: Understanding the Pathway Source Type: research

Treatment of Brain Metastases [REVIEW ARTICLES]
Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with increased surveillance and improved systemic control, the incidence is likely to grow. Despite multimodal treatment, prognosis remains poor. Current evidence supports use of whole-brain radiation therapy when patients present with multiple BMs. However, its associated cognitive impairment is a major deterrent in patients likely to live longer than 6 months. In patients with oligometastases (one to three metastases) and even some with multiple lesions less than 3 to 4 cm, especially if the primary tumor is considered radiotherapy resistant, s...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Lin, DeAngelis Tags: Brain Tumors REVIEW ARTICLES Source Type: research

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study [Hematologic Malignancy]
Conclusion Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Sehn, Goy, Offner, Martinelli, Caballero, Gadeberg, Baetz, Zelenetz, Gaidano, Fayad, Buckstein, Friedberg, Crump, Jaksic, Zinzani, Padmanabhan Iyer, Sahin, Chai, Fingerle-Rowson, Press Tags: Biologic Therapy Hematologic Malignancy Source Type: research

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma [Hematologic Malignancy]
This study evaluates the benefit of novel agent–based CT versus fixed duration of therapy (FDT) in patients with newly diagnosed myeloma. Methods We included patients enrolled onto three phase III trials that randomly assigned patients to novel agent–based CT versus FDT. Primary analyses were restricted to the intent-to-treat population eligible for CT (patients progression free and alive at 1 year after random assignment). Primary end points were PFS1, PFS2, and OS. All hazard ratios (HRs) and 95% CIs were adjusted for several potential confounders using Cox models. Results In the pooled analysis of the thre...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Palumbo, Gay, Cavallo, Di Raimondo, Larocca, Hardan, Nagler, Petrucci, Hajek, Pezzatti, Delforge, Patriarca, Donato, Cerrato, Nozzoli, Yu, Boccadifuoco, Caravita, Benevolo, Guglielmelli, Vincelli, Jacques, Dimopoulos, Ciccone, Musto, Corradini, Cavo, Bocc Tags: Diagnosis & Staging, Chemotherapy Hematologic Malignancy Source Type: research

Safety of Infusing Ipilimumab Over 30 Minutes [Immunotherapy]
Conclusion Ipilimumab at 3 mg/kg can be infused safely over 30 minutes with an acceptably low incidence of IRRs. After an IRR, patients can safely receive additional doses of ipilimumab with premedication. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Momtaz, Park, Panageas, Postow, Callahan, Wolchok, Chapman Tags: Quality of Care, Chemotherapy Immunotherapy Source Type: research

Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology [Thoracic Oncology]
Conclusion We found generally that limited resection is not equivalent to lobectomy in older patients with invasive non–small-cell lung cancer ≤ 2 cm in size, although segmentectomy may be equivalent in patients with adenocarcinoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Veluswamy, Ezer, Mhango, Goodman, Bonomi, Neugut, Swanson, Powell, Beasley, Wisnivesky Tags: Quality of Care, Screening, Surgery, Pathology Thoracic Oncology Source Type: research

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection [Thoracic Oncology]
Purpose The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and WHO is based on the predominant histologic pattern—lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)—present in the tumor. This classification has not been tested in multi-institutional cohorts or clinical trials or tested for its predictive value regarding survival from adjuvant chemotherapy (ACT). Patients and Methods Of 1,766 patients in the IALT, JBR.10, CALGB 9633 (Alliance), and ANITA ACT tr...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Tsao, Marguet, Le Teuff, Lantuejoul, Shepherd, Seymour, Kratzke, Graziano, Popper, Rosell, Douillard, Le-Chevalier, Pignon, Soria, Brambilla Tags: Diagnosis & Staging, Surgery, Chemotherapy, Pathology Thoracic Oncology Source Type: research

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study [Urologic Oncology]
Conclusion Trebananib plus sunitinib seemed to increase toxicity at the tested doses. Efficacy results suggest a potential benefit for the addition of trebananib to sunitinib. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Atkins, Gravis, Drosik, Demkow, Tomczak, Wong, Michaelson, Choueiri, Wu, Navale, Warner, Ravaud Tags: Urologic Oncology Source Type: research

Identifying Social Distress: A Cross-Sectional Survey of Social Outcomes 12 to 36 Months After Colorectal Cancer Diagnosis [Gastrointestinal Cancer]
Purpose To establish the prevalence and determinants of poor social outcomes after a diagnosis of colorectal cancer (CRC). Patients and Methods All 12- to 36-month survivors of CRC (International Classification of Diseases [10th revision] codes C18 to C20) diagnosed in 2010 or 2011 and treated in the English National Health Service were identified and sent a questionnaire from their treating cancer hospital. This included the Social Difficulties Inventory, a 16-item scale of social distress (SD) comprising everyday living, money matters, and self and others subscales, plus five single items. Sociodemographic and clinical ...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Wright, Downing, Morris, Corner, Richards, Sebag-Montefiore, Finan, Glaser Tags: Epidemiology, Quality of Life Gastrointestinal Cancer Source Type: research

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance) [Gastrointestinal Cancer]
Purpose Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. Methods Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was asses...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Pachman, Qin, Seisler, Smith, Beutler, Ta, Lafky, Wagner-Johnston, Ruddy, Dakhil, Staff, Grothey, Loprinzi Tags: Supportive Care, Chemotherapy Gastrointestinal Cancer Source Type: research

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors [Phase I and Clinical Pharmacology]
Conclusion This is the first report of AZD1775 single-agent activity in patients carrying BRCA mutations. Proof-of-mechanism was demonstrated by target modulation and DNA damage response in paired tumor biopsies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Do, Wilsker, Ji, Zlott, Freshwater, Kinders, Collins, Chen, Doroshow, Kummar Tags: Phase I and Clinical Pharmacology Source Type: research

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors [Phase I and Clinical Pharmacology]
Conclusion JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clinical responses were observed, demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Tabernero, Bahleda, Dienstmann, Infante, Mita, Italiano, Calvo, Moreno, Adamo, Gazzah, Zhong, Platero, Smit, Stuyckens, Chatterjee-Kishore, Rodon, Peddareddigari, Luo, Soria Tags: Phase I and Clinical Pharmacology Source Type: research

A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial [Breast Cancer]
This study explored whether dyspareunia is introital pain, preventable with analgesic liquid. Patients and Methods In a randomized, controlled, double-blind trial, estrogen-deficient breast cancer survivors with severe penetrative dyspareunia applied either saline or 4% aqueous lidocaine to the vulvar vestibule for 3 minutes before vaginal penetration. After a 1-month blinded trial of patient-assessed twice-per-week tampon insertion or intercourse, all patients received lidocaine for 2 months in an open-label trial. The primary outcome was patient-related assessment of penetration pain on a scale of zero to 10. Secondary ...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Goetsch, Lim, Caughey Tags: Quality of Life, Menopausal Symptoms Breast Cancer Source Type: research

Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) [Breast Cancer]
Purpose The American College of Surgeons Oncology Group Z1071 trial reported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1 disease. Patients were not selected for surgery based on response, but a secondary end point was to determine whether axillary ultrasound (AUS) after NAC after fine-needle aspiration cytology can identify abnormal nodes and guide patient selection for SLN surgery. Patients and Methods Patients with T0-4, N1-2, M0 breast cancer underwent AUS after neoadjuvant chemotherapy. AUS images were centrally reviewed and classified as normal o...
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Boughey, Ballman, Hunt, McCall, Mittendorf, Ahrendt, Wilke, Le-Petross Tags: Diagnosis & Staging, Surgery Breast Cancer Source Type: research

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer [Rapid Communications]
Conclusion Men with favorable-risk prostate cancer should be informed of the low likelihood of harm from their diagnosis and should be encouraged to consider surveillance rather than curative intervention. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Tosoian, Mamawala, Epstein, Landis, Wolf, Trock, Carter Tags: Rapid Communications Source Type: research

Sentinel Node Biopsy After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Does Axillary Ultrasound Improve Performance? [ONCOLOGY GRAND ROUNDS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Koslow Mautner, Cody Tags: Oncology Grand Rounds Source Type: research

Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Lewin, Siu Tags: Phase I and Clinical Pharmacology EDITORIALS Source Type: research

Sex: Taboos, Assumptions, and Evidence [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Bezjak, Ferguson Tags: EDITORIALS Source Type: research

Does a Picture Make a Difference? Ultrasound Guidance in the Management of the Axilla After Neoadjuvant Chemotherapy [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Harvey, Wolff Tags: Diagnosis & Staging, Surgery, Chemotherapy EDITORIALS Source Type: research

Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: D'Amico Tags: EDITORIALS Source Type: research

Choroidal Metastases From EML4-ALK-Positive Non-Small-Cell Lung Adenocarcinoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Rao, Gragoudas Tags: Radiation, Chemotherapy, Combined Modality, Translational Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research